Skip to main content

Advertisement

Table 3 Effect of cilostazol vs. placebo on anthropometric and metabolic parameters

From: Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial

  Mean difference 95% CI for the difference P-value
BMI (kg/m2) 0.29 −0.03 to 0.61 0.08
Waist circumference (cm) 0.88 −0.28 to 2.03 0.13
Systolic blood pressure (mmHg) 0.76 −4.95 to 6.47 0.79
Diastolic blood pressure (mmHg) 3.07 −1.75 to 7.90 0.21
Fasting glucose (mg/dL) −3.60 −17.04 to 9.84 0.59
HbA1c (%)* −0.01 −0.05 to 0.03 0.53
Fasting insulin (μIU/mL)* 0.07 −0.12 to 0.25 0.45
HOMA-IR* 0.06 −0.17 to 0.29 0.59
QUICKI −0.00 −0.01 to 0.01 0.70
Total cholesterol (mg/dL) −1.21 −11.46 to 9.05 0.81
Triglyceride (mg/dL)* 0.05 −0.15 to 0.26 0.61
HDL-C (mg/dL) 0.98 −3.54 to 5.51 0.66
LDL-C (mg/dL) −0.71 −9.65 to 8.24 0.87
hsCRP (mg/L)* −0.38 −0.84 to 0.09 0.11
Mean baPWV (cm/sec) 31.42 −55.67 to 118.50 0.47
Adiponectin (ng/mL)* −0.07 −0.17 to 0.03 0.16
IL-6 (pg/mL)* −0.18 −0.61 to 0.26 0.38
TNF-α (ng/dL)* −0.08 −0.22 to 0.06 0.27
MCP-1 (ng/dL)* 0.08 −0.11 to 0.27 0.41
sVCAM-1 (ng/dL) 105.18 10.65 to 199.71 0.03
sICAM-1 (ng/dL)* 0.06 −0.05 to 0.18 0.28
  1. HOMA-IR homeostasis model assessment of insulin resistance, QUICKI, quantitative insulin sensitivity check index, hsCRP high sensitivity C-reactive protein, baPWV brachial-ankle pulse wave velocity, IL-6 interleukin-6, TNF-α tumor necrosis factor-alpha, MCP-1 monocyte chemotactic protein-1, sVCAM-1 soluble vascular cellular adhesion molecule-1, sICAM-1 soluble intercellular adhesion molecule-1.
  2. Mean difference = placebo-cilostazol.
  3. *Statistical significance was estimated after logarithmic transformation.